Agendia expands capacity for personalised diagnostic assay
Amsterdam – Dutch molecular diagnostics company Agendia NV has received the green light to use its MammaPrint breast cancer recurrence assay on Agilent microarray scanners and Agilent Bioanalyzers. The additional clearance will expand laboratory capacity for carrying out MammaPrint, TargetPrint, and BluePrint tests in Agendias labs in Irvine and Amsterdam. MammaPrint is a chip based gene expression pattern of 70 cancer related genes that was initially approved by the FDA in 2007 as in vitro diagnostic multivariate index assay device for breast cancer prognosis. The test is able to identify chemotherapy-sensitive metastasis risk with 94% accuracy.